Clinical Trial Update: Immune and Genomic Markers in ALK+ NSCLC

View source ↗

Summary

A Massachusetts General Hospital-led clinical trial on immune and genomic markers in ALK-positive non-small cell lung cancer is currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer | Status: ACTIVE_NOT_RECRUITING